Mergers and acquisitions – Page 12
-
Business
Valeant heads off Endo bid for Salix
Bid raised to $15.8 billion in cash after rival offer from Irish firm
-
BusinessAbbVie to buy Pharmacyclics for pipeline boost
$21bn deal gives AbbVie a share in sales of blockbuster cancer drug as its own biggest sellers face patent expiry
-
Business
Mallinckrodt to buy Ikaria to expand in US hospitals
$2.3bn deal brings nitric oxide ventilator system for newborns with respiratory failure
-
Business
J&J to sell cardiac devices to wholesaler Cardinal
Commodity technology no longer fits with company’s focus on growth and innovation
-
Business
Asahi Kasei to buy Polypore for battery materials
$2.2bn deal adds to Japanese consolidation in energy storage
-
Business
BMS bolsters immuno-oncology with pair of deals
Firm will acquire Flexus Biosciences and collaborate with Rigel
-
Business
Valeant to buy Salix for $14.5bn
Companies expect $500m in savings through ‘R&D rationalisation’
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
Business
WR Grace to split in half
Two daughter companies will focus on catalysts and speciality construction chemicals
-
Business
Tronox to buy FMC’s alkali chemicals
$1.6bn deal helps Tronox strengthen its inorganics portfolio as FMC shifts towards agrochemicals
-
BusinessRoche chases bolt-on acquisitions as it pushes into genomics
Company’s recent shopping spree aims to harness genome sequencing to advance personalised treatments
-
Business
Shire deepens rare disease focus with NPS buyout
Approval of parathyroid hormone drug further validates acquisition decision
-
Business
Biogen Idec to buy Convergence for pain pipeline
UK firm will remain intact as a ‘centre of excellence’ in pain R&D for Biogen
-
-
-
BusinessMerck & Co to buy antibiotics specialist Cubist
Pharma giant remains committed to $9.5bn deal despite key Cubist patents being invalidated by court ruling
-
Business
Saint-Gobain surprises Sika with buyout bid
Company is buying out family-owned controlling stake, but Sika claims the deal will create a conflict of interest
-
Business
Otsuka to buy neurology specialist Avanir
$3.5bn deal adds to Otsuka’s mental health portfolio and strengthens its US presence
-
Business
UCB sells speciality generics subsidiary
Firm will use $1.5bn proceeds to reduce debt and concentrate on developing new drugs in neurology and immunology
-
BusinessActavis rescues Allergan with $66 billion deal
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price